Join our daily newsletter At The Bell to receive exclusive market insights
Digital healthcare pioneer BlinkLab (ASX:BB1) has partnered with US-based Turning Pointe Autism Foundation to conduct a clinical study on autism diagnostics ahead of its FDA registration study later this year.
The study aims to enroll up to one hundred children previously diagnosed with autism and one hundred children without autism.
Turning Pointe Autism Foundation, established in 2007 in Naperville, Illinois, is dedicated to providing tailored programs for individuals with autism aged 5 to 22. Their commitment to enhancing independence and social interaction has positively impacted hundreds of children, teens, and adults with autism across the US.
By partnering with Turning Pointe, BlinkLab is hoping to integrate its innovative neurobehavioral tests into the foundation’s programs. These tests, conducted through smartphones, promise to revolutionize accessibility to diagnostic tools down the track.
The information sourced from this collaboration will play a crucial role in finalizing data collection and processing algorithms, as well as artificial intelligence/machine learning (AI/ML) models. These advancements are essential for BlinkLab’s upcoming FDA registrational study, which is scheduled for the second half of 2024.
“I am excited to see that our first substantive news following our listing a few weeks ago is a collaboration with this prestigious group in the field of autism research in children,” Chairman of BlinkLab Brian Leedman said.
“I anticipate many more important announcements such as these as we get closer to the commencement of our FDA registration study later this year,” he added.
BB1 has been trading at 30 cents.
